[go: up one dir, main page]

CY1123176T1 - Antimikpobiako πεπτιδιο και συνθεσεις αυτου - Google Patents

Antimikpobiako πεπτιδιο και συνθεσεις αυτου

Info

Publication number
CY1123176T1
CY1123176T1 CY20201100692T CY201100692T CY1123176T1 CY 1123176 T1 CY1123176 T1 CY 1123176T1 CY 20201100692 T CY20201100692 T CY 20201100692T CY 201100692 T CY201100692 T CY 201100692T CY 1123176 T1 CY1123176 T1 CY 1123176T1
Authority
CY
Cyprus
Prior art keywords
present
compositions
peptide
antimicrobial
hiv
Prior art date
Application number
CY20201100692T
Other languages
English (en)
Inventor
Hongran Fan Stone
Jacob M. Waugh
Original Assignee
Revance Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revance Therapeutics, Inc. filed Critical Revance Therapeutics, Inc.
Publication of CY1123176T1 publication Critical patent/CY1123176T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει αντιμικροβιακά πεπτίδια που επιδεικνύουν ευρύ φάσμα αντιμικροβιακής δράσης σε βακτήρια θετικά κατά gram και αρνητικά κατά gram, καθώς και σε μύκητες, ευρωτομύκητες και ιούς. Το αντιμικροβιακό πεπτίδιο της εφεύρεσης είναι ένα κατιονικό πεπτίδιο και μπορεί να περιέχει μια αλληλουχία HIV-TAT ή μια αντίστροφη αλληλουχία HIV-TAT ή ένα παράγωγο αυτής. Η παρούσα εφεύρεση παρέχει επίσης αντιμικροβιακές συνθέσεις που περιέχουν το κατιονικό πεπτίδιο. Τέτοιες συνθέσεις είναι ιδιαίτερα χρήσιμες για τοπική εφαρμογή στο δέρμα, τα μαλλιά, τα νύχια, τον κόλπο, την ουρήθρα, το αυτί, τη στοματική κοιλότητα, τη ρινική δίοδο, το αναπνευστικό σύστημα, την οφθαλμική περιοχή και διάφορες περιοχές του βλεννογόνου. Οι συνθέσεις της παρούσας εφεύρεσης βελτιώνουν την κατάσταση ή/και την όψη της θεραπευόμενης περιοχής και είναι κατάλληλες για μακρά ή/και τακτική χρήση, για παράδειγμα, για την πρόληψη μικροβιακής λοίμωξης ή για την αποτροπή της επανεμφάνισης αυτής. Η παρούσα εφεύρεση παρέχει επίσης κιτ για χρήση στη βελτίωση της κατάστασης ή της όψης του δέρματος, του νυχιού ή της θεραπευόμενης περιοχής. Αυτά τα κιτ μπορούν να διευκολύνουν τη χρήση, τη μακρά αποθήκευση ή/και την αποτελεσματικότητα των συνθέσεων.
CY20201100692T 2007-07-26 2020-07-27 Antimikpobiako πεπτιδιο και συνθεσεις αυτου CY1123176T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95205907P 2007-07-26 2007-07-26
PCT/US2008/071350 WO2009015385A1 (en) 2007-07-26 2008-07-28 Antimicrobial peptide, compositions , and methods of use
EP08826608.5A EP2178549B1 (en) 2007-07-26 2008-07-28 Antimicrobial peptide and compositions thereof

Publications (1)

Publication Number Publication Date
CY1123176T1 true CY1123176T1 (el) 2021-10-29

Family

ID=40281862

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161101296T CY1118503T1 (el) 2007-07-26 2016-12-14 Αντιμικροβιακο πεπτιδιο και συνθεσεις αυτου
CY20201100692T CY1123176T1 (el) 2007-07-26 2020-07-27 Antimikpobiako πεπτιδιο και συνθεσεις αυτου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20161101296T CY1118503T1 (el) 2007-07-26 2016-12-14 Αντιμικροβιακο πεπτιδιο και συνθεσεις αυτου

Country Status (24)

Country Link
US (1) US8623811B2 (el)
EP (3) EP2178549B1 (el)
JP (5) JP5401457B2 (el)
KR (4) KR20170016031A (el)
CN (2) CN101842107B (el)
AU (1) AU2008278593B2 (el)
BR (3) BRPI0813627B1 (el)
CA (1) CA2694046C (el)
CO (1) CO6260098A2 (el)
CR (1) CR11239A (el)
CY (2) CY1118503T1 (el)
DK (2) DK3120862T3 (el)
ES (2) ES2609914T3 (el)
HR (1) HRP20161722T1 (el)
HU (1) HUE031136T2 (el)
IL (3) IL203173A (el)
LT (1) LT2178549T (el)
MX (1) MX2010000916A (el)
NZ (1) NZ582459A (el)
PL (1) PL2178549T3 (el)
PT (2) PT3120862T (el)
SG (1) SG188128A1 (el)
SI (1) SI2178549T1 (el)
WO (1) WO2009015385A1 (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598159A (en) * 2006-12-29 2013-08-30 Revance Therapeutics Inc Transport molecules using reverse sequence hiv-tat polypeptides
PL2178549T3 (pl) * 2007-07-26 2017-03-31 Revance Therapeutics, Inc. Peptyd przeciwdrobnoustrojowy i jego kompozycje
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
AU2009223161B2 (en) 2008-03-14 2014-10-30 Allergan, Inc. Immuno-based botulinum toxin serotype A activity assays
HUE037595T2 (hu) 2008-12-31 2018-09-28 Revance Therapeutics Inc Injektálható botulinum toxin készítmények
MX2011010335A (es) 2009-04-01 2012-01-12 Revance Therapeutics Inc Metodos y composiciones para tratar afecciones de la piel asociadas con hiperreactividad vascular.
SI2440231T1 (sl) 2009-06-10 2020-08-31 Nono Inc. Sočasno dajanje sredstva, vezanega na internalizacijski peptid tat, z inhibitorjem degranulacije mastocitov
MX366344B (es) 2009-06-25 2019-07-05 Revance Therapeutics Inc Formulaciones de toxina botulinica libres de albumina.
US10022083B2 (en) 2011-06-02 2018-07-17 Abdulmohsen E. A. H. Al-Terki Multiple oral and nasal surgical procedures method and kit
US8387798B1 (en) 2012-04-27 2013-03-05 Abdulmohsen E. A. H. Al-Terki Mutiple oral and nasal surgical procedures method and kit
FR2997304B1 (fr) 2012-10-26 2017-07-07 Isp Investments Inc Utilisation d’un extrait de lin, en tant qu’agent actif activateur de la synthese de peptides antimicrobiens
CA2889833A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US20140242110A1 (en) * 2013-02-28 2014-08-28 Dt Scimed, Llc Dose, localization, and formulation of botulinum toxins in skin and muscle
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
CN116077630A (zh) * 2015-09-17 2023-05-09 抗非特公司 具有对抗革兰氏阴性菌的活性的溶素多肽
US10105381B2 (en) * 2016-05-23 2018-10-23 Cmpd Licensing, Llc Compositions and methods for treating an infection
US10144767B2 (en) * 2016-08-18 2018-12-04 Board Of Regents Of The University Of Nebraska Anti-microbial peptides and coatings
KR102487144B1 (ko) * 2016-11-21 2023-01-12 에이리온 테라퓨틱스, 인코포레이티드 큰 물질의 경피 전달
EP3675900A4 (en) 2017-08-28 2021-05-05 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
CN107556374B (zh) * 2017-08-30 2020-02-07 四川大学 唾液富脯蛋白仿生防龋功能多肽、其衍生物和盐及其应用
CN107353334B (zh) * 2017-08-30 2020-02-07 四川大学 基于唾液富酪蛋白的仿生防龋多肽、其衍生物和盐及应用
JP7266202B2 (ja) * 2018-02-19 2023-04-28 株式会社ファンケル 化粧料及び抗炎症剤
AU2021252544A1 (en) * 2020-04-08 2022-11-03 Amicrobe, Inc. Compositions and uses of locally applied synthetic amino acid polymers for prevention and treatment of viral infections
WO2025059665A1 (en) 2023-09-15 2025-03-20 Revance Therapeutics, Inc. Serial treatment with botulinum toxin for cervical dystonia
WO2025064729A1 (en) 2023-09-19 2025-03-27 Revance Therapeutics, Inc. Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance
WO2025072381A1 (en) 2023-09-25 2025-04-03 Revance Therapeutics, Inc. Methods for determining influence of carrier peptide on the binding of a therapeutic protein to a cell membrane

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5747641A (en) * 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
WO1993021941A1 (en) * 1992-04-23 1993-11-11 Allelix Biopharmaceuticals Inc. Treatment of herpesvirus infection
EP0903408A3 (en) 1992-08-21 2005-11-02 Biogen, Inc. Tat-derived transport polypeptide
WO1995011038A1 (en) * 1993-10-22 1995-04-27 Allelix Biopharmaceuticals Inc. Treatment of cytomegalovirus infection
DE69434443T2 (de) 1993-12-28 2006-05-24 Allergan, Inc., Irvine Verwendung der neutrotoxischen Komponente des Botulinum Toxins zur Muskelschmerzbehandlung
US6232295B1 (en) 1994-10-12 2001-05-15 Jon Faiz Kayyem Cell-specific contrast agent and gene delivery vehicles
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
WO1997008199A2 (en) * 1995-08-23 1997-03-06 University Of British Columbia Antimicrobial cationic peptides and methods of screening for the same
US6043218A (en) * 1996-10-22 2000-03-28 Medical University Of South Carolina Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides
GB9623051D0 (en) 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
JP2002505077A (ja) * 1997-12-10 2002-02-19 ワシントン大学 抗病原体システムおよびその使用方法
EP1044280A1 (en) * 1997-12-12 2000-10-18 Onyx Pharmaceuticals, Inc. SELECTIVE KILLING AND DIAGNOSIS OF p53?+ NEOPLASTIC CELLS
JP2002528421A (ja) 1998-10-27 2002-09-03 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 創傷治癒の促進方法
CA2354044A1 (en) 1998-12-10 2000-06-15 Washington University Protein transduction system and methods of use thereof
BR9816113A (pt) 1998-12-23 2001-10-23 Idea Ag Formulação aperfeiçoada para aplicação tópica não-invasiva in vivo
US7056656B1 (en) * 1999-01-25 2006-06-06 University Of Medicine And Dentistry Of New Jersey Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
US20030236214A1 (en) * 1999-06-09 2003-12-25 Wolff Jon A. Charge reversal of polyion complexes and treatment of peripheral occlusive disease
US7008924B1 (en) * 1999-07-21 2006-03-07 Amgen, Inc. VGF fusion polypeptides
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6544548B1 (en) * 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6844324B1 (en) * 1999-11-12 2005-01-18 Massachusetts Institute Of Technology Modular peptide mediated intracellular delivery system and uses therefore
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6670322B2 (en) * 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US20030215412A1 (en) * 2000-07-21 2003-11-20 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
EP2364734B1 (en) 2000-07-21 2017-09-06 ReVance Therapeutics, Inc. Multi-component biological transport systems
US6696038B1 (en) * 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US20020127247A1 (en) * 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
WO2002065986A2 (en) 2001-02-16 2002-08-29 Cellgate, Inc. Transporters comprising spaced arginine moieties
EP1401281A4 (en) * 2001-05-09 2004-12-29 Univ Yale TOLL / INTERLEUKIN-1 RECEPTOR ADAPTER PROTEIN (TIRAP)
US7060498B1 (en) * 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7169814B2 (en) * 2001-12-11 2007-01-30 The Board Of Trustees Of The Leland Stanford Junior University Guanidinium transport reagents and conjugates
WO2003072049A2 (en) 2002-02-21 2003-09-04 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
US20030215395A1 (en) * 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
JP4154218B2 (ja) * 2002-11-27 2008-09-24 寛紀 高麗 新規抗菌性ポリペプチドとその利用
IL153557A0 (en) * 2002-12-19 2003-07-06 Yitzchak Hillman Antibodies and antagonists to antimicrobial peptides for the purpose of treating, inhibiting and preventing auto immune diseases
MXPA05006359A (es) * 2002-12-19 2006-02-08 Yitzchak Hillman Tratamiento de la enfermedad a traves de inhibidores peptidos antimicrobianos.
PL378571A1 (pl) * 2003-02-01 2006-05-02 Neuralab Limited Czynna immunizacja dla wytworzenia przeciwciał przeciw rozpuszczalnemu A-ß
WO2004084805A2 (en) * 2003-03-19 2004-10-07 The J. David Gladstone Institutes Acetylated tat polypeptides and methods of use thereof
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
ZA200602754B (en) * 2003-09-12 2007-06-27 Univ British Columbia Effectors of innate immunity determination
JP2005120050A (ja) * 2003-10-20 2005-05-12 Toagosei Co Ltd 新規抗菌性ペプチドとその利用
US8092788B2 (en) 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
PT2985039T (pt) 2004-03-03 2018-11-09 Revance Therapeutics Inc Aplicação tópica e administração transdérmica de toxinas botulínicas
PT1778720E (pt) * 2004-08-18 2010-11-29 Novabiotics Ltd Péptidos antimicrobianos compreendendo um motivo com arginina e/ou lisina
EP1656951A1 (en) * 2004-11-12 2006-05-17 Xigen S.A. Conjugates with enhanced cell uptake activity
CA2629751A1 (en) 2004-11-12 2006-05-18 The University Of British Columbia Antimicrobial peptides
EP1661912A1 (en) 2004-11-29 2006-05-31 Xigen S.A. Fusion protein comprising a BH3-domain of a BH3-only protein
JP4730584B2 (ja) * 2004-12-06 2011-07-20 東亞合成株式会社 抗菌ペプチド及びその利用
JP2006238751A (ja) * 2005-03-02 2006-09-14 Toagosei Co Ltd ベロ毒素結合性を有する抗菌ペプチド及びその利用
SG160357A1 (en) 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
CN101160318A (zh) 2005-03-03 2008-04-09 雷文斯治疗公司 用于局部施用和经皮肤递送寡肽的组合物和方法
KR20080006568A (ko) 2005-03-30 2008-01-16 레반스 테라퓨틱스, 아이엔씨. 여드름 치료용 조성물 및 방법
NZ568216A (en) 2005-11-17 2012-09-28 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
NZ598159A (en) 2006-12-29 2013-08-30 Revance Therapeutics Inc Transport molecules using reverse sequence hiv-tat polypeptides
CN101616682A (zh) 2006-12-29 2009-12-30 雷文斯治疗公司 用源自hiv-tat的多肽片段稳定的肉毒杆菌毒素的组合物及其局部施用和透皮递送的方法
PL2178549T3 (pl) * 2007-07-26 2017-03-31 Revance Therapeutics, Inc. Peptyd przeciwdrobnoustrojowy i jego kompozycje
HUE037595T2 (hu) 2008-12-31 2018-09-28 Revance Therapeutics Inc Injektálható botulinum toxin készítmények

Also Published As

Publication number Publication date
JP5965884B2 (ja) 2016-08-10
AU2008278593A1 (en) 2009-01-29
US8623811B2 (en) 2014-01-07
BRPI0813627A2 (pt) 2014-12-23
PT2178549T (pt) 2016-12-20
SG188128A1 (en) 2013-03-28
CA2694046C (en) 2023-09-12
DK3120862T3 (da) 2020-06-22
ES2609914T3 (es) 2017-04-25
PT3120862T (pt) 2020-06-25
JP2017002057A (ja) 2017-01-05
JP2019006791A (ja) 2019-01-17
AU2008278593A2 (en) 2011-05-12
AU2008278593B2 (en) 2015-04-09
HK1180237A1 (zh) 2013-10-18
JP6722241B2 (ja) 2020-07-15
CN101842107A (zh) 2010-09-22
CN102872447B (zh) 2015-09-30
EP2178549B1 (en) 2016-09-14
WO2009015385A1 (en) 2009-01-29
CY1118503T1 (el) 2017-07-12
IL223784A (en) 2015-02-26
JP2010534684A (ja) 2010-11-11
BR122019000258B1 (pt) 2021-09-14
BRPI0813627B1 (pt) 2021-09-14
US20100215591A1 (en) 2010-08-26
KR101717275B1 (ko) 2017-03-16
PL2178549T3 (pl) 2017-03-31
LT2178549T (lt) 2017-01-25
EP2178549A4 (en) 2014-02-19
EP3120862B1 (en) 2020-04-29
CA2694046A1 (en) 2009-01-29
EP2178549A1 (en) 2010-04-28
JP5401457B2 (ja) 2014-01-29
IL223785A (en) 2015-02-26
HUE031136T2 (en) 2017-07-28
SI2178549T1 (sl) 2017-08-31
KR20170016031A (ko) 2017-02-10
KR101722038B1 (ko) 2017-04-03
IL203173A (en) 2014-12-31
EP3741380A1 (en) 2020-11-25
HRP20161722T1 (hr) 2017-02-10
CN101842107B (zh) 2014-04-23
DK2178549T3 (en) 2017-01-09
CR11239A (es) 2010-06-29
BR122019000266B1 (pt) 2021-09-14
JP2014076993A (ja) 2014-05-01
JP2020169190A (ja) 2020-10-15
EP3120862A1 (en) 2017-01-25
KR102088949B1 (ko) 2020-03-13
NZ582459A (en) 2012-05-25
KR20180031824A (ko) 2018-03-28
KR20100047867A (ko) 2010-05-10
MX2010000916A (es) 2010-06-02
CO6260098A2 (es) 2011-03-22
ES2805225T3 (es) 2021-02-11
CN102872447A (zh) 2013-01-16
KR20150090268A (ko) 2015-08-05

Similar Documents

Publication Publication Date Title
CY1123176T1 (el) Antimikpobiako πεπτιδιο και συνθεσεις αυτου
Gawande et al. Antibiofilm and antimicrobial efficacy of DispersinB®-KSL-W peptide-based wound gel against chronic wound infection associated bacteria
ES2582555T3 (es) Conservantes para composiciones cosméticas, de tocador y farmacéuticas
CY1121447T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
NO20083245L (no) Sykliske antimikrobielle peptider
WO2006121610A3 (en) Personal care compositions and methods for their use
CY1105221T1 (el) Ιατρικη χρηση θυρεοειδομιμητικων ενωσεων για την θepαπευτικη αγωγη της τριχοπτωσης και φαρμακευτικες συνθεσεις
BR0012674A (pt) Formulações farmacêuticas preservadas
WO2011047868A3 (en) Peptides used in the treatment and/or care of the skin, mucous membranes and/or hair and its use in cosmetic or pharmaceutical compositions
AU2020217620B2 (en) Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes
WO2017125585A3 (en) Novel polypeptides and medical uses thereof
UY26269A1 (es) Formulación de sal común y moxifloxacina
ATE333863T1 (de) Zusammensetzungen enthaltend ein ethanolaminderivat sowie organische metallsalze
BRPI0405939A (pt) Formulações antibacterianas de uso tópico
WO2008029064A3 (fr) Utilisation topique d'un extrait peptidique de soja et/ou de ble comme agent photoprotecteur
CY1118930T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
CN110078794A (zh) 一种抗菌肽及其应用
ES2741656T3 (es) Niacinamida para inducir la generación de péptidos antimicrobianos
ES2979393T3 (es) Composición antimicrobiana
DK1169340T3 (da) Lantibiotikum
NO20065662L (no) Esterlinkede makrolider nyttige for behandlingen av mikrobielle infeksjoner
ATE285786T1 (de) Säugetierabkömmliche peptide zur behandlung von mikrobiellen infektionen
WO2007082864A3 (en) Use of chavicol as an antiseptic
BR112014007491A2 (pt) sequências de aminoácidos para o controle de patógenos